Early to growth-stage private equity across life sciences and healthcare fund research profile
Kotak Life Sciences Fund I is a healthcare-focused private-equity vehicle launched by Kotak Alternate Asset Managers in 2025. It targets early to growth-stage businesses across life sciences and healthcare, with public manager and company announcements confirming investments in Mediversal Healthcare and Zeroharm Sciences.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Kotak Life Sciences Fund I uses a early to growth-stage private equity across life sciences and healthcare approach across Pharmaceuticals, medical devices, diagnostics, digital health.
Current evidence
Kotak Alternate Asset Managers announced a fund investment in Zeroharm Sciences in February 2026; the manager also announced a fund investment in Mediversal Healthcare in November 2025.
Strategy
Early to growth-stage private equity across life sciences and healthcare
Sector focus
Pharmaceuticals, medical devices, diagnostics, digital health
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Kotak Alternate Asset Managers announced a fund investment in Zeroharm Sciences in February 2026; the manager also announced a fund investment in Mediversal Healthcare in November 2025.
Investor questions
Kotak Life Sciences Fund I is covered in Rupeia's private equity research universe. The current public record describes the strategy as Early to growth-stage private equity across life sciences and healthcare, with a sector focus of Pharmaceuticals, medical devices, diagnostics, digital health. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Kotak Life Sciences Fund I in the reviewed public sources: Mediversal Healthcare; Zeroharm Sciences. It does not represent a complete current portfolio unless the manager has published one.
Public announcements confirm the fund’s first close in January 2025 and named investments in Mediversal Healthcare and Zeroharm Sciences in 2025–2026. Fund-level performance and exits are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: INR 1,600 crore target; INR 250 crore first close, as reported by Kotak Alternate Asset Managers; final close and fund-level NAV are not publicly disclosed.. Public terms or access information: Category II AIF with an early-to-growth-stage life-sciences and healthcare mandate; ticket sizes, fees, carry, reserves and holding period are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Ashish Ranjan (Partner, healthcare and life sciences); Lakshmi Iyer (Kotak Alternate Asset Managers leadership); Srini Sriniwasan (Managing Director). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: The complete portfolio, final close, fund-level net returns, fees, carry, reserves and current allocation terms are not publicly disclosed. Only Mediversal Healthcare and Zeroharm Sciences are included because Kotak or attributable company announcements identify the fund vehicle directly..
2026-02-18: Kotak Alternate Asset Managers announced a fund investment in Zeroharm Sciences in February 2026; the manager also announced a fund investment in Mediversal Healthcare in November 2025.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.